From Operating Room to Oval Office: Dr. Oz to Lead Medicare & Medicaid
- Abigail Hahm
- May 9
- 4 min read

Dr. Mehmet Oz, a cardiothoracic surgeon turned Emmy-winning TV host, has taken on the appointment as 17th Administrator of the Centers for Medicare and Medicaid Services (CMS). Dr. Oz, whose face became a fixture on daytime television, has now assumed an appointment that has ignited both intrigue and apprehension.
Despite a conspicuous absence of formal health policy credentials, Dr. Oz's extensive experience treating Medicare and Medicaid patients during his years in New York City has positioned him well to lead the agency as its 17th administrator.
Holding an MD and MBA from the University of Pennsylvania, Dr. Oz cultivated a distinguished career in cardiothoracic surgery. However, his professional narrative took a dramatic turn with his foray into media, beginning with appearances on the Discovery Channel and Oprah Winfrey's talk show. This eventually culminated in his own syndicated program, "The Dr. Oz Show," launched in 2009. While the show garnered a vast audience by addressing lifestyle health topics such as diabetes and weight loss, it also drew sharp criticism for promoting unsubstantiated and potentially misleading health advice. Nonetheless, Dr. Oz's undeniable ability to connect with and inspire viewers solidified his status as a household name.
His transition to the political arena became more pronounced in 2021, when he launched an unsuccessful bid for the U.S. Senate in Pennsylvania. Though the campaign did not yield electoral success, it served as a significant pivot point in his career, laying the groundwork for his current appointment as CMS administrator.

Leading The CMS
In this new role, Dr. Oz shoulders the weighty responsibility of overseeing Medicare and Medicaid, programs that provide essential health coverage to millions of Americans. His primary mandate is to ensure the efficient operation and long-term sustainability of these programs, addressing any emerging threats to their effectiveness. While his public pronouncements on Medicaid funding have been somewhat vague, he has expressed a commitment to preserving the program for its intended beneficiaries. This stance aligns with President Trump's stated priorities of "loving and cherishing" Medicare and Medicaid while simultaneously targeting waste, fraud, and abuse.
Dr. Oz's tenure at CMS will undoubtedly be marked by significant challenges, including navigating potential budget cuts and addressing the ongoing complexities of Medicaid expansion under the Affordable Care Act. His relative lack of direct health policy experience may pose an obstacle in tackling intricate issues such as funding allocations, state-federal dynamics, and the diverse needs of beneficiary populations. The appointment has elicited a spectrum of reactions, as the future of Medicare and Medicaid resonates deeply with Americans across the political spectrum. The extent to which Dr. Oz's unconventional background will shape the direction of these vital programs remains to be seen, making his leadership a subject of intense scrutiny and speculation.
Read more about the impact of federal research funding cuts on the future of medicine and learn about the most anticipated drug launches of 2025.
Further Reading:
If you liked this article:
Share this article with your network on LinkedIn with your thoughts or perspectives. Make sure to tag us @HealthcareInsights to join the conversation.
Subscribe to our free newsletter, HealthcareIn Quicktakes. You'll never miss an article, and will get access to exclusive reports.
Check out our library of articles and reports on biotech, healthcare, policy, and business.
Who We Are: At Healthcare Insights, we're covering the transformation of healthcare and bringing our readers the most pertinent takes on key issues in medicine, biotech, healthcare policy, and business. Our Spotlight Series ✦ features thoughts from the most influential figures in healthcare, including Nobel Prize-winning scientists shaping tomorrow's treatments and business leaders bringing new therapies to market. We strive to publish coverage that is authentic, impartial, and independent of any financial or political motive. For more information regarding our editorial standards, read our statement. If you'd like to contact the Editor, use this form to get in touch.
If you'd like to stay in the loop, make sure to subscribe to our free newsletter, HealthcareIn Quicktakes, and follow us @healthcareinsights across our social channels, including LinkedIn.
©️ Copyright 2025 Healthcare Insights
All Rights Reserved
Legal Disclaimer:
The information provided in this article has been collected from various academic publications, industry reports/analyses, regulatory guidelines, media coverage, and legal analyses. The information provided is for general information purposes only and should not be construed for medical, legal, financial, or professional advice. Readers are advised to seek independent professional guidance where relevant. While we strive to ensure the accuracy and timeliness of our coverage, we claim no liability, representations, or warranties of any kind about the completeness, suitability, accuracy, reliability, authorship, or availability of this article and all pertaining data within this article. Neither the author nor the publication will assume liability for any loss or damage arising from the use of the information provided in the article. The information within this article may be outdated or inaccurate over time, and neither the author nor the publication are obligated to update or revise such information. We reserve the right to modify, remove, or substantially edit the article, including the disclaimer, at any time.

Commentaires